Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy
- Cite this article as:
- Apostolopoulos, V., Sandrin, M. & McKenzie, I. J Mol Med (1999) 77: 427. doi:10.1007/s001090050373
- 60 Downloads
Recent clinical studies with mannan mucin immunotherapeutic agents indicate that patients produce predominantly antibody responses while mice produce a high cytotoxic T lymphocyte response. In studying the reason for the ’immune deviation’ occurring in mice to humans from cellular to antibody responses, it has been found that natural anti-Galα(1,3)Gal antibodies, present in all humans, react with the mucin component of the agent, providing an example of a carbohydrate-peptide mimic. The immune deviation can be overcome by in vitro sensitization of antigen-presenting cells in the absence of anti-Gal antibodies – at least in mice. The review examines the background of these observations and discusses other peptide carbohydrate mimics and immune deviation
Unable to display preview. Download preview PDF.